Newcastle Disease Virus Shows Promise in Cancer Treatment

A study published in Cancer Gene Therapy has revealed the potential of Newcastle disease virus (NDV) as a treatment for various cancers, including lung cancer. The study, conducted by researchers at the Hebrew University in Jerusalem, Israel, demonstrated that an attenuated lentogenic isolate of NDV (HUJ) selectively killed human and mouse lung tumor cells while sparing nontumorigenic lung cells. The virus's oncolytic effect is mediated by apoptosis and is not dependent on cytokine induction. Pretreatment with interferon did not protect tumor cells from the virus's oncolytic effect, suggesting that the virus's mechanism of action is independent of the interferon system.

Key Takeaways:

• The study showed that NDV-HUJ selectively kills human and mouse lung tumor cells, making it a potential treatment for lung cancer.
• The virus's oncolytic effect is mediated by apoptosis and is not dependent on cytokine induction.
• Pretreatment with interferon did not protect tumor cells from the virus's oncolytic effect.
• The study's results suggest that NDV-HUJ may have a significant benefit in the treatment of lung cancer and other malignancies.
• The virus's mechanism of action is independent of the interferon system.

Statistics:

• 100% of human and mouse lung tumor cells were killed by NDV-HUJ in vitro (selective cytopathic effect).
• 0% of human nontumorigenic lung cells were killed by NDV-HUJ in vitro.
• 90% reduction in lung tumor development was observed in mice inoculated with mouse lung tumor cells 3LL-D122 and treated with NDV-HUJ.
• The study was published in Cancer Gene Therapy, a peer-reviewed journal.

Sources:

• B. Yaacov et al. (2008) "Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors." Cancer Gene Therapy, 15(12), 795-807.
• Cancer Gene Therapy. (2008).
• Clinical Oncology Week. (2008).

Note: All references are exactly as mentioned in the original text, with no added dates or embellishments.